Exact Sciences reported 23% year-over-year revenue growth for Q4 2025 and confirmed a special shareholder vote on its proposed $23 billion acquisition by Abbott. The company posted $878.4 million in Q4 revenue and said screening products and precision oncology tests drove gains. CEO Kevin Conroy said the company is building momentum as it integrates product expansion and prepares for the Abbott deal. Investors will watch the Feb. 20 shareholder meeting to assess approval risk and any regulatory or financing contingencies tied to the transaction. Exact’s adjusted EPS missed Street estimates, and its adjusted profitability metrics will be scrutinized as Abbott evaluates long-term synergies with its diagnostics franchise. The filing and results crystallize where consolidation is heading in cancer diagnostics: larger diagnostics incumbents buying growth platforms. The vote outcome will determine near-term strategic direction for Exact’s screening and precision oncology businesses.